TEL AVIV, Israel, Oct. 8, 2014 /PRNewswire/ -- Cell Source,
Inc. (OTCQB: CLCS) ("Cell Source") an immunotherapy and
regenerative medicine company, announced today its President and
CEO, Itamar Shimrat, will present at
two upcoming conferences in New York
City during the month of October.
On Tuesday, October
28th at 10:30 am
Mr. Shimrat will present at the FireRock Conference, New York City's premier annual micro-cap
conference. The conference is an exclusive gathering of the "Who's
who" of the micro-cap space, with a lineup of industry leaders,
standout companies and cutting edge speakers and panelists.
Companies and attendees interested in the conference are invited to
view the conference flier, and register at the
conference's website.
On Wednesday, October
29th, at 10:45 am,
Mr. Shimrat will present at the Life Sciences Summit,
an investor and business development conference that
highlights innovation. The objective of the event is to connect
biotech and academic innovators with capital and strategic
partners. The two-day program features corporate presentations by
promising young companies with transformative science that targets
unmet medical needs. It also features informative plenary sessions,
business workshops, and Key Opinion Leader sessions.
For further information, please visit
www.cell-source.com or contact Itamar
Shimrat, President & CEO (646) 416-7896.
About Cell Source, Inc.
Cell Source is an immunotherapy and regenerative medicine
company whose primary breakthrough is the regulation of immune
tolerance. In preclinical studies Cell Source's therapies have
demonstrated the ability to directly address a number of severe
medical conditions including blood cancers such as non-Hodgkins
lymphoma, multiple myeloma, and chronic lymphocytic leukemia.
Cell Source's organ regeneration platform holds the potential
to repair organs and to grow entire organs inside the patient's
body. Growing or regenerating organs and using cell therapy to
tolerize the immune system can each revolutionize the treatment of
numerous severe diseases that today kill hundreds of thousands of
patients annually.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
ACT OF 1995
With the exception of historical information,
the matters discussed in this news release are
forward-looking statements that involve a number
of risks and uncertainties. The actual future results of
Cell Source could differ significantly from those statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the
inability to finance the company's
operations, inability to hire and retain qualified personnel,
and changes in the general economic climate. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," the negative of
such terms, or other comparable terminology. These
statements are only predictions. Although we believe that the
expectations reflected in the forward-looking statements
are reasonable, such statements should not be regarded as a
representation by Cell Source, or any other person, that such
forward-looking statements will be achieved. We undertake no duty
to update any of the forward-looking statements, whether as a
result of new information, future events or otherwise. In light of
the foregoing, readers are cautioned not to place undue reliance on
such forward-looking statements. This release does not
constitute an offer to sell or a solicitation of offers to buy any
securities of any entity.
SOURCE Cell Source, Inc.